Announcements Trials
Browse Landscape

Status

Recruiting 11Active not recruiting 6Terminated 5Withdrawn 3Completed 2Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

fludarabine phosphate 3venetoclax 2navitoclax 2fludarabine 2zanubrutinib 1sugemalimab 1plerixafor 1nilotinib 1midostaurin 1loncastuximab tesirine 1eryaspase 1ceritinib 1asparaginase erwinia chrysanthemi recombinant 1Whole-Body Irradiation 1Tacrolimus 1Mycophenolic Acid 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1Brentuximab Vedotin 1Bone Marrow Transplantation 1Bendamustine Hydrochloride 1Asparaginase 1AP 1903 reagent 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × loncastuximab tesirine × Lymphoid × Clear all
NCT04705454 2021-05-12

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics S.A.

No longer available
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡